All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Florida Cancer Specialists & Research Institute Opens Sixth Clinic Location in Pasco County

September 19th 2022

Florida Cancer Specialists & Research Institute, LLC held a ribbon-cutting ceremony on August 18, 2022 to celebrate the opening of its newest clinical site in Pasco County.

Immunotherapy Drives First-line Systemic Treatment for Advanced HCC

September 19th 2022

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

Geography Should Not Be Destiny

September 18th 2022

To really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.

Relatlimab Plus Nivolumab Approved in Europe for Unresectable or Metastatic Melanoma with PD-L1 <1%

September 17th 2022

The European Commission has approved the fixed-dose combination of relatlimab plus nivolumab for use in the frontline treatment of select patients with advanced or metastatic melanoma and a PD-L1 expression of less than 1% on tumor cells.

FDA Grants Orphan Drug Status to SY-5609 for Pancreatic Cancer

September 16th 2022

The FDA has granted an orphan drug designation to the CDK7 inhibitor SY-5609 for use as a potential therapeutic option in patients with relapsed metastatic pancreatic cancer.

From Anguish to Action: Turning Despair Into Efforts to Improve Racial Equity

September 16th 2022

Oncology fellows at the University of North Carolina turned their despair over the murders of George Floyd and Breonna Taylor into an effort to improve racial equity.

Atezolizumab and Bevacizumab TRAEs are Potential Predictors of Favorable Outcomes in HCC

September 16th 2022

Patients with hepatocellular carcinoma who developed treatment-related adverse effects associated with atezolizumab plus bevacizumab had improved overall survival and progression-free survival outcomes.

EMA Grants Orphan Drug Designation to CAN-2409 for Glioma

September 16th 2022

The European Medicines Agency Committee for Orphan Medical Products has granted an orphan drug designation to CAN-2409 for the treatment of patients with glioma.

Jefferson Names Joseph G. Cacchione, MD, New CEO of Jefferson Health and Thomas Jefferson University

September 16th 2022

Dr. Cacchione Will Lead Jefferson in Shaping the Future of Healthcare, Higher Education and Discovery

Changes Improve Radiation Therapy in SCLC

September 16th 2022

Investigators are making progress in delineating the optimal use of radiation therapy for the treatment of patients with small cell lung cancer, which remains a cornerstone of therapy for the malignancy, particularly in limited-stage disease.

Dose-Optimized Regorafenib Leads to Improved Survival in mCRC

September 16th 2022

Dose optimization of regorafenib led to improved survival outcomes compared with best supportive care of fruquintinib, standard-dose regorafenib, and trifluridine/tipiracil in patients with relapsed/refractory metastatic colorectal cancer.

FDA Streamlines Regulatory Process for Envafolimab in Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma

September 15th 2022

The FDA has granted a fast track designation to envafolimab for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma and myxofibrosarcoma who have progressed on 1 or 2 prior lines of chemotherapy.

Durvalumab/Chemo Triplet Signifies Novel Advances in Treatment of Biliary Tract Cancer

September 15th 2022

Mark Yarchoan, MD, lays out the evolution of drug development in biliary tract cancer, discusses the findings from the TOPAZ-1 trial, and shares the positive future direction of immunotherapy in this disease.

Pembrolizumab/Axitinib Combo Represents Promising First-line Option for Papillary or Chromophobe mRCC

September 15th 2022

Pembrolizumab plus axitinib produced promising responses in patients with papillary or chromophobe metastatic renal cell carcinoma.

New Chief of Blood Disorders Named to New Jersey’s Only NCI-Designated Comprehensive Cancer Center

September 15th 2022

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health have appointed Matthew Matasar, MD, MS, as Chief of Blood Disorders at New Jersey’s leading cancer center and the only one in the state designated as a Comprehensive Cancer Center by the National Cancer Institute.

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15th 2022

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

Nivolumab Elicits Statistically Significant Improvement in RFS in Stage IIB/C Melanoma

September 15th 2022

Adjuvant nivolumab monotherapy elicited a statistically significant and clinically meaningful improvement in recurrence-free survival compared with placebo for patients with completely resected stage IIB/C melanoma.

Progress on New Therapies Stirs Hope in SCLC

September 15th 2022

During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.

Lasofoxifene Plus Abemaciclib Shows Encouraging Efficacy in Locally Advanced or Metastatic ESR1-Mutated, ER+ Breast Cancer

September 15th 2022

Lasofoxifene plus abemaciclib produced promising efficacy when administered to pre- and postmenopausal patients with locally advanced or metastatic, estrogen receptor–positive, HER2-negative breast cancer who harbored an ESR1 mutation.

Fellows’ Passion Keeps Deol Sharp and Up to Date

September 14th 2022

Abhinav Deol, MD, discusses how Karmanos Cancer Institute prepares trainees for their first job and helps them handle negative situations and deal with grief.